Inhibitor Therapeutics INTI
OTC INTI
$0.09 -0.02 (-18.18%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Revenue (2018)

Updated

Analysis

Inhibitor Therapeutics (INTI) Revenue (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,147.74 Bn 1,116.33 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 636.22 Bn 556.08 Bn 17.30 Bn 25.40 Bn
3 AbbVie 502.73 Bn 475.84 Bn 12.70 Bn 16.99 Bn
4 Merck 357.93 Bn 312.30 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 301.67 Bn 265.66 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 264.02 Bn 237.70 Bn 12.86 Bn 15.38 Bn
7 Amgen 239.31 Bn 194.70 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 194.97 Bn 169.17 Bn 6.22 Bn 7.80 Bn
9 Pfizer 171.63 Bn 118.27 Bn 10.94 Bn 15.03 Bn
10 Inhibitor Therapeutics 15.64 Mn 8.46 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 3,320.00
Sep 30, 2018 3,995.00
Jun 30, 2018 2,490.00
Mar 31, 2018 4,222.00
API Access

Inhibitor Therapeutics Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=INTI&period=max&api_key=YOUR_API_KEY